Glaukos (NYSE:GKOS) Issues Earnings Results

Posted by Stanley Muller on Jul 31st, 2026

Glaukos (NYSE:GKOS – Get Free Report) released its quarterly earnings data on Wednesday. The medical instruments supplier reported ($0.14) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.07, FiscalAI reports. The business had revenue of $185.61 million for the quarter, compared to the consensus estimate of $150.93 million. Glaukos had a negative return on equity of 6.33% and a negative net margin of 30.68%.The company’s revenue was up 49.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.24) EPS.

Here are the key takeaways from Glaukos’ conference call:

Record second-quarter sales reached $185.6 million, up 50% year over year, prompting Glaukos to raise full-year 2026 revenue guidance to $680 million–$700 million from $620 million–$635 million.
U.S. glaucoma sales rose 64% to $118.5 million, with iDose TR contributing approximately $74 million. Management expects iDose TR revenue of roughly $275 million–$280 million for 2026, supported by expanding surgeon adoption and commercial and Medicare Advantage utilization.
Epioxa generated approximately $11 million in its first full commercial quarter, while the broader corneal health franchise is now expected to grow about 20% year over year in 2026. The company reported treatment-center coverage reaching roughly 85% of the U.S. population and payer access covering more than 125 million commercial lives.
The transition from Photrexa and a miscellaneous billing code to Epioxa’s permanent J-code is expected to create volatility or a temporary “air pocket” in third-quarter corneal revenue, with improvement anticipated in the fourth quarter and into 2027.
Potential Medicare coverage restrictions for iDose TR remain an important uncertainty, as proposed local coverage determinations from five of seven Medicare Administrative Contractors include criteria the company opposes. International glaucoma growth may also face competitive trialing, reimbursement pressure in Germany and Switzerland, and fading foreign-exchange tailwinds.

Glaukos Trading Down 0.9%

Shares of NYSE GKOS traded down $1.56 during trading hours on Friday, reaching $166.96. The stock had a trading volume of 396,123 shares, compared to its average volume of 884,544. Glaukos has a 52-week low of $73.16 and a 52-week high of $184.00. The firm has a market cap of $9.81 billion, a price-to-earnings ratio of -51.40 and a beta of 0.75. The business’s fifty day moving average price is $137.20 and its two-hundred day moving average price is $124.78. The company has a current ratio of 5.43, a quick ratio of 4.73 and a debt-to-equity ratio of 0.10.

Insider Buying and Selling at Glaukos

In other Glaukos news, CFO Alex R. Thurman sold 10,000 shares of Glaukos stock in a transaction on Thursday, July 16th. The stock was sold at an average price of $160.00, for a total transaction of $1,600,000.00. Following the completion of the sale, the chief financial officer directly owned 43,906 shares of the company’s stock, valued at $7,024,960. The trade was a 18.55% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Gilbert H. Kliman sold 5,000 shares of the stock in a transaction on Thursday, May 14th. The stock was sold at an average price of $140.76, for a total value of $703,800.00. Following the transaction, the director directly owned 35,528 shares in the company, valued at $5,000,921.28. The trade was a 12.34% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 40,000 shares of company stock worth $6,028,800 over the last 90 days. 5.90% of the stock is currently owned by company insiders.

Institutional Trading of Glaukos

Hedge funds have recently bought and sold shares of the stock. Abel Hall LLC bought a new position in shares of Glaukos in the 4th quarter worth $321,000. XTX Topco Ltd purchased a new position in Glaukos in the fourth quarter valued at about $308,000. CIBC Asset Management Inc bought a new position in Glaukos in the fourth quarter worth about $307,000. O Shaughnessy Asset Management LLC acquired a new stake in Glaukos in the fourth quarter valued at approximately $289,000. Finally, Quantinno Capital Management LP purchased a new position in Glaukos in the second quarter worth $276,000. Hedge funds and other institutional investors own 99.04% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on GKOS shares. Stifel Nicolaus raised their target price on shares of Glaukos from $175.00 to $190.00 and gave the company a “buy” rating in a report on Thursday. Citigroup lifted their price objective on shares of Glaukos from $175.00 to $188.00 and gave the stock a “buy” rating in a research note on Thursday. Weiss Ratings restated a “sell (d-)” rating on shares of Glaukos in a research report on Friday, July 17th. Piper Sandler reaffirmed an “overweight” rating and issued a $195.00 price target (up from $165.00) on shares of Glaukos in a report on Thursday. Finally, Truist Financial lifted their price target on Glaukos from $180.00 to $215.00 and gave the stock a “buy” rating in a research report on Thursday. Twelve research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $177.33.

Read Our Latest Analysis on GKOS

About Glaukos

(Get Free Report)

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.